Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$23.69 USD
-0.40 (-1.64%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $23.64 -0.05 (-0.21%) 5:06 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VKTX 23.69 -0.40(-1.64%)
Will VKTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Where Does VKTX Stock Stand After the Obesity Pill Setback?
Other News for VKTX
VKTX forms Stochastic Reached Oversold on September 15
VKTX's price falls by 3.61% on September 12, though its technical setup remains stable.
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
SA Asks: Which biotechs could be acquired by year's end?
Is VKTX building bearish momentum? 180 Bearish Setup shows up after declining 0.5%